Ibopamine

We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 461851

CAS#: 66195-31-1 (free base)

Description: Ibopamine is a sympathomimetic drug, designed as a prodrug of epinine, used in ophthalmology. It induces mydriasis.


Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-10-29. Prices are subject to change without notice.

Ibopamine is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 461851
Name: Ibopamine
CAS#: 66195-31-1 (free base)
Chemical Formula: C17H25NO4
Exact Mass: 307.1784
Molecular Weight: 307.39
Elemental Analysis: C, 66.43; H, 8.20; N, 4.56; O, 20.82


Related CAS #: 75011-65-3 (HCl)   66195-31-1 (free base)   66195-35-5 (HBr)   106175-82-0 (citrate)   862420-20-0 (maleate))    

Synonym: Ibopamine; Ibopamino; Ibopaminum; SB 7505; SB-7505; SB7505;

IUPAC/Chemical Name: 4-(2-(methylamino)ethyl)-1,2-phenylene bis(2-methylpropanoate)

InChi Key: WDKXLLJDNUBYCY-UHFFFAOYSA-N

InChi Code: InChI=1S/C17H25NO4/c1-11(2)16(19)21-14-7-6-13(8-9-18-5)10-15(14)22-17(20)12(3)4/h6-7,10-12,18H,8-9H2,1-5H3

SMILES Code: CNCCC1=CC=C(OC(C(C)C)=O)C(OC(C(C)C)=O)=C1


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.03.00


References

1: Landers J, Ullrich K, Craig JE. Ibopamine challenge testing differentiates glaucoma suspect, stable glaucoma and progressive glaucoma cases. Clin Exp Ophthalmol. 2015 Dec;43(9):808-14. doi: 10.1111/ceo.12569. Epub 2015 Jul 27. PubMed PMID: 26140527.

2: Landers J, Ullrich K, Craig JE. Ibopamine challenge testing becomes negative following successful trabeculectomy surgery. Clin Exp Ophthalmol. 2016 Apr;44(3):166-9. doi: 10.1111/ceo.12684. Epub 2016 Feb 12. PubMed PMID: 26575026.

3: Domínguez-Dueñas F, Plaza-Espinosa L, Mundo-Fernández EE, Jiménez-Reynoso CA, Barojas-Weber E, Barrientos-Gutiérrez T. Early Glaucoma Screening Using the Ibopamine Provocative Test. J Glaucoma. 2016 May;25(5):e441-5. doi: 10.1097/IJG.0000000000000343. PubMed PMID: 26709501.

4: Ullrich K, Craig JE, Landers J. Ibopamine challenge test can be used to differentiate glaucoma suspects from glaucoma patients. Clin Exp Ophthalmol. 2014 May-Jun;42(4):342-6. doi: 10.1111/ceo.12200. Epub 2013 Oct 8. PubMed PMID: 24034130.

5: Virno M, Sampaolesi R, Pecori Giraldi J, De Gregorio F, Taloni M, Brusini P, Di Staso S, Stecchi G. Ibopamine: D1-dopaminergic agonist in the diagnosis of glaucoma. J Glaucoma. 2013 Jan;22(1):5-9. doi: 10.1097/IJG.0b013e3182311db4. PubMed PMID: 21946546.

6: Giuffrè I, Falsini B, Gari MA, Balestrazzi E. Pattern electroretinogram assessment during ibopamine test in ocular hypertension. Eur J Ophthalmol. 2013 Nov-Dec;23(6):819-22. doi: 10.5301/ejo.5000334. Epub 2013 Jun 24. PubMed PMID: 23813108.

7: Bhosai SJ, Lin CC, Greene J, Bloomer MM, Jeng BH. Rapid corneal adrenochrome deposition from topical ibopamine in the setting of infectious keratitis. Eye (Lond). 2013 Jan;27(1):105-6. doi: 10.1038/eye.2012.217. Epub 2012 Oct 19. PubMed PMID: 23079754; PubMed Central PMCID: PMC3545386.

8: Scuderi GL, Regine F, Perdicchi A, Turtoro A, Contestabile MT. Efficacy of 2% ibopamine on the dilation of patients with pseudoexfoliation syndrome. Eur J Ophthalmol. 2010 Jan-Feb;20(1):120-3. PubMed PMID: 19882519.

9: Ganteris-Gerritsen E, Ugahary LC, Jansen J, Mulder PG, Cohen AF, van Meurs JC. Six months treatment with ibopamine in patients with hypotony after vitreoretinal surgery for retinal detachment, uveitis or penetrating trauma. Retina. 2012 Apr;32(4):742-7. doi: 10.1097/IAE.0b013e3182265177. PubMed PMID: 21909052.

10: Alicandri C, Fariello R, Boni E, Zaninelli A, Muiesan G. Ibopamine vs. digoxin in chronic heart failure: a double-blind, crossover study. J Cardiovasc Pharmacol. 1989;14 Suppl 8:S77-82. PubMed PMID: 2483444.

11: Girbes AR, Van Veldhuisen DJ, Grevink RG, Smith AJ, Reitsma WD. Effects of ibopamine on exercise-induced increase in norepinephrine in normal men. J Cardiovasc Pharmacol. 1992 Mar;19(3):371-4. PubMed PMID: 1378116.

12: Influence of ibopamine on heart rate and arrhythmic pattern in patients with congestive heart failure. A double-blind multicentre study. G Ital Cardiol. 1989 Jan;19(1):71-80. PubMed PMID: 2663585.

13: Wehling M, Zimmermann J, Weil J, Gerzer R, Theisen K. [Renal effects of ibopamine in comparison with furosemide in patients with mild heart failure]. Z Kardiol. 1990 Feb;79(2):120-5. German. PubMed PMID: 2157313.

14: Parker JO. The effects of oral ibopamine in patients with mild heart failure--a double blind placebo controlled comparison to furosemide. The Ibopamine Study Group. Int J Cardiol. 1993 Jul 15;40(3):221-7. PubMed PMID: 8225657.

15: Pigini MA, Avila MP, Magacho L. [Effects of 2% ibopamine eye drops on the results of computerized visual field]. Arq Bras Oftalmol. 2009 May-Jun;72(3):365-9. Portuguese. PubMed PMID: 19668968.

16: Pouleur H. Neurohormonal and hemodynamic effects of ibopamine. Clin Cardiol. 1995 Mar;18(3 Suppl I):I17-21. Review. PubMed PMID: 7743694.

17: Spencer C, Faulds D, Fitton A. Ibopamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in congestive heart failure. Drugs Aging. 1993 Nov-Dec;3(6):556-84. Review. PubMed PMID: 7906158.

18: Azzollini F, De Caro L, Longo A, Pelosi G, Rolandi E, Ventresca GP, Lodola E. Ibopamine kinetics after single and multiple dosing in patients with congestive heart failure. Int J Clin Pharmacol Ther Toxicol. 1988 Nov;26(11):544-51. PubMed PMID: 3243658.

19: van Gilst WH, van Veldhuisen DJ, Hegeman H, Buikema H, Scholtens E, de Graeff PA, Lie KI. Effect of ibopamine on ventricular remodeling after experimental myocardial infarction: a comparison with captopril. J Cardiovasc Pharmacol. 1994 Jul;24(1):171-4. PubMed PMID: 7521484.

20: Lieverse AG, van Veldhuisen DJ, Smit AJ, Zijlstra JG, Meijer S, Reitsma WD, Lie KI, Girbes AR. Renal and systemic hemodynamic effects of ibopamine in patients with mild to moderate congestive heart failure. J Cardiovasc Pharmacol. 1995 Mar;25(3):361-7. PubMed PMID: 7769799.